Entera Health, Inc
12
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
3 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
33%
3 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate in Healthy Adults
Role: lead
Evaluating the Impact of EnteraGam In People With COVID-19
Role: lead
To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients
Role: collaborator
Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA
Role: collaborator
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
Role: collaborator
To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease
Role: lead
Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy
Role: lead
Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
Role: collaborator
SBI in Children With d-IBS
Role: collaborator
Retrospective Study of IBS-D Patients Previously Receiving SBI
Role: lead
Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPD
Role: collaborator
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
Role: collaborator
All 12 trials loaded